A large prospective cohort study that includes specific lung cancer populations stratified by stage, histology, treatment modality, or the timing of repeat KL-6 testing is needed to verify the usefulness of serial KL-6 monitoring during or after cancer treatment. This evidence concerns the gene MUC1 and lung cancer.